Detection of Lung Cancer Risks for Serum Metabolomics

血清代谢组学检测肺癌风险

• 批准号: 7787700
• 负责人: Leo L Cheng
• 金额: $ 24.77万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-01-01 至 2011-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7787700
• 关键词: Adenocarcinoma; Biochemistry; Biological; Blood; Blood Tests; Blood specimen; Cancer Control; Cancer Detection; Cancer Intervention and Surveillance Modeling Network; Cancer Patient; Cancerous; Cardiac Output; Clinic; Clinical; Coupled; Data; Detection; Development; Diagnosis; Disease; Eligibility Determination; Future; General Population; Genomics; Goals; Histopathology; Knowledge; Lesion; Lung; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Malignant Neoplasms; Malignant neoplasm of lung; Measures; Metabolic; Methods; Modeling; Monitor; Non-Small-Cell Lung Carcinoma; Pathology; Patients; Positron-Emission Tomography; Reading; Reporting; Research; Resources; Risk; Sampling; Screening procedure; Sensitivity and Specificity; Serum; Specimen; Squamous cell carcinoma; Staging; Structure of parenchyma of lung; Survival Rate; Symptoms; Techniques; Testing; Time; Tissues; base; cancer proteomics; cancer risk; cancer type; clinical application; cost; design; disorder control; economic outcome; health economics; innovation; lung cancer screening; member; metabolomics; mortality; prevent; public health relevance; research study; success; tool

DESCRIPTION (provided by applicant): The alarmingly high lung cancer mortality rate is due mostly to the lack of effective screening protocols for the general public that can detect and diagnose the condition at early and asymptomatic stages. Current radiological examinations, including CT, MRI, and PET, can detect lesions in the lungs; however, their extremely high costs coupled with their unproven efficacies as screening tools have prevented their use in annual screening protocols for the general public. Analyses of blood samples may be a practical and acceptable resource for advancements in lung cancer screening that can advise patients with suspicious readings to seek immediate further radiological tests. In the era of genomics and proteomics, cancer metabolomics collectively evaluate the biological statuses of global metabolite alterations related to malignancy development and progression. Metabolomic profiles measured from cancerous tissues have shown better sensitivity in assessing patient clinical conditions than current histopathology. The aim of the proposed project is to establish lung cancer specific blood serum metabolomic profiles with enough sensitivity and specificity to indicate the necessity for further radiological tests. In this preliminary and exploratory study, we will analyze paired tissue and serum specimens from the same lung cancer patients by using a magnetic resonance spectroscopy method that we developed for intact specimen analyses, search and discover lung cancer tissue metabolomic profiles in connection with tissue pathologies, apply the parameters of these metabolomic profiles obtained from tissue to their corresponding serum spectroscopic data, and test these calculated serum profiles for their ability to identify and group cancer patients. The project is designed to test the hypothesis that serum metabolomic profiles calculated from tissue metabolomic profiles and corrected by quantitative tissue pathologies may have clinical applicability as an early lung cancer screening test for the general public prior to the development of disease symptoms. The specific aims of the project are: 1) To establish serum metabolomic profiles according to tissue metabolomic profiles measured from the same patients for SCC and adenocarcinoma; and 2) to evaluate the sensitivity and specificity of the established serum metabolite profiles for detection and categorization of lung cancers from these patients, and assess and evaluate the clinical utility of the researched lung cancer serum metabolomic marker for screening, using a model from the NCI's Cancer Intervention and Surveillance Modeling Network (CISNET). PUBLIC HEALTH RELEVANCE: This is an exploratory study of paired tissue and serum samples from various lung cancer patients. If successful, annual screening of serum metabolomic profiles established through the initiatives of this project will direct patients with suspicious serum profiles to advanced and expensive radiological tests to detect lung cancers at early and asymptomatic stages, and in turn increase overall patient survival rates and change the paradigm of current oncological clinics.

描述(申请人提供)：肺癌死亡率高得惊人，主要是由于缺乏有效的一般公众筛查方案，可以在早期和无症状阶段发现和诊断病情。目前的放射学检查，包括CT、MRI和PET，可以发现肺部的病变；然而，它们的极高成本，加上它们作为筛查工具的未经证实的有效性，阻碍了它们在普通公众的年度筛查方案中的使用。血样分析可能是肺癌筛查进步的一个实用和可接受的资源，可以建议读数可疑的患者立即寻求进一步的放射检查。在基因组学和蛋白质组学时代，肿瘤代谢组学共同评估与恶性肿瘤发展和进展相关的全球代谢物变化的生物学状态。从癌症组织中测量的代谢组特征在评估患者临床状况方面比目前的组织病理学表现出更好的敏感性。该项目的目的是建立肺癌特异性血清代谢谱，具有足够的敏感性和特异性，以表明进一步放射检查的必要性。在这项初步和探索性研究中，我们将使用我们为完整标本分析而开发的磁共振波谱方法分析来自同一肺癌患者的配对组织和血清样本，搜索并发现与组织病理相关的肺癌组织代谢组谱，将从组织中获得的这些代谢组谱的参数应用于相应的血清光谱数据，并测试这些计算的血清谱对癌症患者进行识别和分组的能力。该项目旨在检验这样一种假设，即根据组织代谢组谱计算并经定量组织病理学校正的血清代谢组谱可能具有临床适用性，可以作为在疾病症状出现之前对普通公众进行早期肺癌筛查的测试。该项目的具体目标是：1)根据从相同的鳞癌和腺癌患者身上测量的组织代谢谱建立血清代谢谱；以及2)评估所建立的血清代谢物谱用于检测和分类这些患者的肺癌的敏感性和特异性，并使用NCI的癌症干预和监测建模网络(CISNET)的模型来评估和评估所研究的肺癌血清代谢组标志物用于筛查的临床实用性。 公共卫生相关性：这是一项对不同肺癌患者的配对组织和血清样本的探索性研究。如果成功，通过该项目的倡议建立的血清代谢图谱的年度筛查将引导血清图谱可疑的患者接受先进且昂贵的放射检查，以在早期和无症状阶段发现肺癌，进而提高患者的总体存活率，并改变目前肿瘤诊所的模式。